Well, Eater is home to a few enthusiastic and judgmental gummy aficionados. At every gas station and airport candy store, for instance our staff writer Amy McCarthy is on the hunt for the best ...

Credit: shisu_ka/Shutterstock. Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise oncology molecular glue therapeutics. The ...

Other pharmas have also put big money into the glue game. In 2024, Eisai signed its own Seed pact worth up to $1.5 billion to go after neurodegeneration and oncology targets.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis. As per the agreement, Lilly will front $40 million, an amount ...